StockUS listing USOMERNASDAQHealthcareProfitless Growth

Omeros Corporation(OMER) Stock Analysis | Healthcare

USD --+0.00%
Reward55Moderate
Risk79High
50%Data
Strong 325% profit margin · Revenue growing 15% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.27Bn
Reward Ratingⓘ55 Moderate reward assessment · 50% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ79 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on OMER to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Omeros Corporation?

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

AI Brief Pro

The brief on Omeros Corporation

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Omeros Corporation?

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.27B, and a P/E ratio of 14.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (55)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio14.3361
Beta2.987
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.